JP2020529988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529988A5 JP2020529988A5 JP2020505233A JP2020505233A JP2020529988A5 JP 2020529988 A5 JP2020529988 A5 JP 2020529988A5 JP 2020505233 A JP2020505233 A JP 2020505233A JP 2020505233 A JP2020505233 A JP 2020505233A JP 2020529988 A5 JP2020529988 A5 JP 2020529988A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- compound according
- group substituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540860P | 2017-08-03 | 2017-08-03 | |
| US62/540,860 | 2017-08-03 | ||
| PCT/US2018/045175 WO2019028357A1 (en) | 2017-08-03 | 2018-08-03 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL DISORDERS AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529988A JP2020529988A (ja) | 2020-10-15 |
| JP2020529988A5 true JP2020529988A5 (enExample) | 2021-09-09 |
| JP7498108B2 JP7498108B2 (ja) | 2024-06-11 |
Family
ID=65233534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505233A Active JP7498108B2 (ja) | 2017-08-03 | 2018-08-03 | 医学的障害の予防および治療のための化合物およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11583530B2 (enExample) |
| EP (1) | EP3661502A4 (enExample) |
| JP (1) | JP7498108B2 (enExample) |
| KR (1) | KR102692840B1 (enExample) |
| CN (1) | CN111032039B (enExample) |
| AU (1) | AU2018309085B2 (enExample) |
| BR (1) | BR112020001698A2 (enExample) |
| CA (1) | CA3069745A1 (enExample) |
| IL (1) | IL272097B2 (enExample) |
| MX (1) | MX2020001256A (enExample) |
| WO (1) | WO2019028357A1 (enExample) |
| ZA (1) | ZA202000375B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI744300B (zh) * | 2016-03-23 | 2021-11-01 | 里爾中央醫學中心 | 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途 |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| JP7498108B2 (ja) | 2017-08-03 | 2024-06-11 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニー | 医学的障害の予防および治療のための化合物およびその使用 |
| JP2022523333A (ja) | 2019-01-30 | 2022-04-22 | トゥルーバインディング，インコーポレイテッド | 抗ｇａｌ３抗体およびその使用 |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| CN113476442A (zh) * | 2021-07-28 | 2021-10-08 | 上海交通大学医学院附属第九人民医院 | 化合物gb-0139在治疗心肌梗死后心肌过度纤维化的药物中的应用 |
| GB2631507A (en) * | 2023-07-04 | 2025-01-08 | Univ Liverpool | Compositions |
| GB2631509A (en) * | 2023-07-04 | 2025-01-08 | Univ Liverpool | Compositions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT377586B (de) | 1981-06-30 | 1985-04-10 | Erba Farmitalia | Verfahren zur herstellung von substituierten pyrrolo-(2,1-b)-chinazolinen und pyrido(2,1-b)chinazolinen |
| ES524262A0 (es) | 1982-08-05 | 1984-11-16 | Erba Farmitalia | "procedimiento para preparar derivados de quinazolina" |
| SE0100172D0 (sv) * | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| KR20040041092A (ko) | 2001-01-31 | 2004-05-13 | 시냅틱 파마세틱칼 코포레이션 | 우울증 및/또는 불안증의 치료를 위한 ｇａｌ3 수용체길항물질의 용도 및 상기와 같은 방법에 유용한 화합물 |
| WO2002060392A2 (en) | 2001-01-31 | 2002-08-08 | Synaptic Pharmaceutical Corporation | Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| NZ538029A (en) | 2002-07-09 | 2006-08-31 | Actelion Pharmaceuticals Ltd | 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives |
| US7220775B2 (en) | 2002-08-07 | 2007-05-22 | H. Lundbeck A/S | Compound useful for the treatment of neuropathic pain |
| DE10304141B4 (de) | 2003-02-03 | 2006-03-09 | Hf Arzneimittelforschung Gmbh | Verfahren zur Herstellung von Chinazolin-Alkaloiden |
| CA2836463A1 (en) | 2011-05-17 | 2012-11-22 | Discoverybiomed Inc. | Treating protein folding disorders with small molecule cftr correctors |
| ES2562903T3 (es) | 2011-07-13 | 2016-03-09 | Santen Pharmaceutical Co., Ltd | Nuevo compuesto que tiene actividad inhibidora de PARP |
| WO2016004093A2 (en) | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
| WO2016120403A1 (en) * | 2015-01-30 | 2016-08-04 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| CN105272986A (zh) | 2015-06-15 | 2016-01-27 | 厦门医学高等专科学校 | 一种可抑制乙酰胆碱酯酶活性的化合物或其制备方法和应用 |
| CN106220631B (zh) | 2016-07-26 | 2019-02-05 | 中山大学 | 一种7位氟取代Isaindigotone衍生物及其制备方法和在制备抗癌药物中的应用 |
| JP7498108B2 (ja) | 2017-08-03 | 2024-06-11 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニー | 医学的障害の予防および治療のための化合物およびその使用 |
-
2018
- 2018-08-03 JP JP2020505233A patent/JP7498108B2/ja active Active
- 2018-08-03 EP EP18841404.9A patent/EP3661502A4/en active Pending
- 2018-08-03 BR BR112020001698-5A patent/BR112020001698A2/pt not_active Application Discontinuation
- 2018-08-03 CA CA3069745A patent/CA3069745A1/en active Pending
- 2018-08-03 IL IL272097A patent/IL272097B2/en unknown
- 2018-08-03 US US16/629,373 patent/US11583530B2/en active Active
- 2018-08-03 AU AU2018309085A patent/AU2018309085B2/en active Active
- 2018-08-03 MX MX2020001256A patent/MX2020001256A/es unknown
- 2018-08-03 CN CN201880050555.3A patent/CN111032039B/zh active Active
- 2018-08-03 WO PCT/US2018/045175 patent/WO2019028357A1/en not_active Ceased
- 2018-08-03 KR KR1020207005279A patent/KR102692840B1/ko active Active
-
2020
- 2020-01-20 ZA ZA2020/00375A patent/ZA202000375B/en unknown
-
2022
- 2022-07-08 US US17/861,023 patent/US12377102B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529988A5 (enExample) | ||
| JP2004529874A5 (enExample) | ||
| JP2020531418A5 (enExample) | ||
| JP2009530398A5 (enExample) | ||
| EP2723340B1 (en) | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | |
| CN113453721B (zh) | Metap2抑制剂的生物标志物及其应用 | |
| EP2343292A1 (en) | Novel prostaglandin i<sb>2</sb>derivative | |
| JP2007508238A5 (enExample) | ||
| TW200944540A (en) | C20-C21 substituted glucocorticoid receptor agonists | |
| RU2013122898A (ru) | Похоксимовые конъюгаты, применимые для лечения связанных с hsp90 патологий, композиция и способ лечения с их помощью | |
| CN101822841B (zh) | 有机胺衍生物作为小分子药物脑靶向修饰基团的用途 | |
| TWI324066B (en) | A pharmaceutical composition for inhibiting cell migration induced by an angiogenic factor | |
| JP2009508902A5 (enExample) | ||
| JP2008506723A (ja) | 医薬用運搬体及び作用体並びに化学用相間移動剤としてのアンモニウム塩及びアンモニウム塩−鉱酸塩クラスレート化合物 | |
| CN104557870B (zh) | 一种吡啶胺化合物的富马酸盐 | |
| JPWO2020231776A5 (enExample) | ||
| EP1005347A1 (en) | Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases | |
| US9376432B2 (en) | Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma | |
| WO2024230728A1 (zh) | 靶向成纤维细胞活化蛋白的配体 | |
| JP2011500841A5 (enExample) | ||
| RU2010120810A (ru) | Гидратированные кристаллические сложные эфиры камптотецина для лечения рака | |
| CN115279761A (zh) | 咪唑并吡啶酮化合物或其盐的晶体 | |
| US11103489B2 (en) | Drug for preventing or treating inflammatory bowel disease | |
| EP4397654A1 (en) | Ep4 antagonist compound as well as salt, polymorph, and use thereof | |
| CN102627682A (zh) | 酯化、卤代豆甾醇衍生物及其在抗癌药物中的应用 |